-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KHygx0T6My1jGiVSIoKbdLGqLmXpe6ekeu8Qa5sqIwBeHTSigc70J85y8qwCKnf+ XHdpqD0XMpbsvd04BELLDA== 0000950162-02-001471.txt : 20021028 0000950162-02-001471.hdr.sgml : 20021028 20021028130205 ACCESSION NUMBER: 0000950162-02-001471 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20021028 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20021028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 02799555 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 shire8k102802.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2002 Shire Pharmaceuticals Group plc - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) England and Wales - -------------------------------------------------------------------------------- (State or other jurisdiction of incorporation) 0-29630 98-0359573 - -------------------------------------- ------------------------------------- (Commission File Number) (IRS Employer Identification No.) Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code 44 1256 894 000 ------------------------------ - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.1 and incorporated by reference herein. Item 7. Financial Statements and Exhibits (c) Exhibits. The following exhibit is filed herewith: 99.1 Press Release dated October 28, 2002 -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 28, 2002 SHIRE PHARMACEUTICALS GROUP PLC By: /s/ Angus Charles Russell ------------------------------------------- Name: Angus Charles Russell Title: Group Finance Director EXHIBIT INDEX Number Description 99.1 Press Release dated October 28, 2002 EX-99.1 3 shire8k102802ex.txt PRESS RELEASE Shire Pharmaceuticals Group plc Hampshire International Business Park, Chineham, Basingstoke RG24 8EP UK Tel +44 1256 894000 Fax +44 1256 894708 http://www.shire.com 28 October 2002 7:00am (UK time) 8:00am (Cont. Europe Time) SHIRE ANNOUNCES VACCINES ALLIANCE 28 October 2002, Basingstoke, UK - Shire Pharmaceuticals Group plc (LSE: SHP L, NASDAQ: SHPGY, TSE: SHQ) announces that it has entered into a commercial agreement with Berna Biotech AG of Switzerland. Under the agreement, Shire will manufacture and supply its FLUVIRAL(R) influenza vaccine to Berna Biotech for sale in international territories excluding Europe and North America. In return, Berna Biotech will manufacture and supply its hepatitis B vaccines, Hepavax Gene* and Bio-Hep B* and make them available to Shire for exclusive sale in Europe. Shire Biologics, part of the Shire Group, began its vaccine operations more than a decade ago when it purchased the vaccine operations of the Armand-Frappier Institute, which had been producing and selling vaccines for many years. Shire Biologics' current commercial products are FLUVIRAL, PACIS(R) for superficial bladder cancer and NEISVAC-C for meningitis C infection. Commenting on the agreement, Richard de Souza, Director International, said: "We are delighted to be linking with Berna Biotech which has over 100 years experience in the development and marketing of vaccines and immunotherapeutics. Through this alliance, Shire will become a more significant player in the vaccines market. The purpose of this deal is to broaden our platform before launching our new and exciting vaccine products now in development. These include SPD 703 for the prevention of pneumococcal meningitis and otitis media in young children and pneumonia and invasive diseases in adults and SPD 704 for the prevention of meningococcal meningitis and invasive diseases in children." Dr Kuno Sommer, CEO at Berna Biotech added: "This alliance is an important step in strengthening our European market presence as well as strengthening our key product franchises." - ENDS - * trade mark of Berna Biotech NeisVac-C is a trademark of Baxter International Inc.
For further information please contact: Global (outside US & Canada) US & Canada Clea Rosenfeld - Investor Relations +44 1256 894 221 Gordon Ngan - Investor Relations +1 450 978 7942 Jessica Mann - Media +44 1256 894 280 Michele Roy - Media +1 450 978 7876
Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international specialty pharmaceutical company with a strategic focus on three therapeutic areas - central nervous system disorders (CNS), oncology and anti-infectives. Shire also has two platform technologies: advanced drug delivery and Biologics. Shire's core strategy is based on research and development combined with in-licensing and a focus on eight key pharmaceutical markets. For further information on Shire, please visit the company's website: Error! Bookmark not defined. Berna Biotech AG Berna AG (Swiss Exchange) develops, produces and markets vaccines and immunotherapeutics for private and public markets world-wide. Headquartered in Berne, Switzerland, with principal sites in Europe and Korea, Berna is a fully-integrated company, employing over 950 people in R&D, regulatory affairs, production, and sales and marketing. Recently expanded through the acquisition of Rhein Biotech, Berna's range of novel and validated proprietary technology platforms supports a strong product portfolio. The company markets five core vaccines in the hepatitis B, influenza and travel franchises, and has a broad development pipeline, including six products in or entering phase III clinical development in 2002. Development is supported through alliances with academic and commercial partners. Error! Bookmark not defined. THE "SAFE HARBOUR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. The statements in this press release that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event that such risks or uncertainties materialise, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialisation, the impact of competitive products, patents, government regulation and approval, and other risks and uncertainties detailed from time to time in periodic reports produced by Shire, including the Annual Report filed on Form 10K by Shire with the Securities and Exchange Commission. -----END PRIVACY-ENHANCED MESSAGE-----